Traws Pharma (TRAW) Net Income towards Common Stockholders (2012 - 2026)
Traws Pharma (TRAW) posted quarterly Net Income towards Common Stockholders of -$5.7 million for Q1 2026, down 137.74% year-over-year from $15.1 million in Q1 2025, and down 5.45% quarter-over-quarter from -$5.4 million in Q4 2025.
Traws Pharma (TRAW) Net Income towards Common Stockholders (2012 - 2026) Analysis & Trends
Traws Pharma (TRAW) has reported Net Income towards Common Stockholders for 15 consecutive years, with -$5.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Income towards Common Stockholders fell 137.74% year-over-year to -$5.7 million; the TTM figure through Mar 2026 stood at -$14.8 million (up 48.32% YoY), while the FY2025 annual figure was $6.9 million, up 112.56% from the prior year.
- Net Income towards Common Stockholders declined to -$5.7 million in Q1 2026 per TRAW's latest filing, from -$5.4 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $15.1 million in Q1 2025 and bottomed at -$175.9 million in Q4 2022.
- Historically, Net Income towards Common Stockholders has averaged -$15.2 million across 5 years, with a median of -$5.0 million in 2024.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders sank 377.78% — and 2025, when it jumped 402.69%.
- Traws Pharma's Net Income towards Common Stockholders stood at -$175.9 million in 2022, then surged by 97.45% to -$4.5 million in 2023, then tumbled by 377.78% to -$21.4 million in 2024, then surged by 74.8% to -$5.4 million in 2025, then declined by 5.45% to -$5.7 million in 2026.
- Business Quant data shows TRAW's Net Income towards Common Stockholders at -$5.7 million in Q1 2026, -$5.4 million in Q4 2025, and -$3.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Traws Pharma | 5.66 Mn | 639,491.99 | - | -2.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.69 Mn |
| Dec 31, 2025 | -5.40 Mn |
| Sep 30, 2025 | -3.04 Mn |
| Jun 30, 2025 | -625,000.00 |
| Mar 31, 2025 | 15.08 Mn |
| Dec 31, 2024 | -21.42 Mn |
| Sep 30, 2024 | -1.43 Mn |
| Jun 30, 2024 | -20.77 Mn |
| Mar 31, 2024 | -4.98 Mn |
| Dec 31, 2023 | -4.48 Mn |
| Sep 30, 2023 | -5.09 Mn |
| Jun 30, 2023 | -4.61 Mn |
| Mar 31, 2023 | -6.14 Mn |
| Dec 31, 2022 | -175.87 Mn |
| Sep 30, 2022 | -5.64 Mn |
| Jun 30, 2022 | -4.12 Mn |
| Mar 31, 2022 | -4.14 Mn |
| Dec 31, 2021 | -177.62 Mn |
| Sep 30, 2021 | -3.99 Mn |
| Jun 30, 2021 | -4.65 Mn |